Long-Term Follow-Up of Cadaveric Breast Augmentation: What Can We Learn? by Modarressi, Ali et al.
Case Report
Long-Term Follow-Up of Cadaveric Breast
Augmentation: What Can We Learn?
Ali Modarressi, MD; Jean Villard, MD; Jean-Christophe Tille, MD, PhD;
and Brigitte Pittet, MD
Abstract
Breast augmentation with cadaveric fat graft has long been available to patients in Eastern European countries, primarily in the Soviet Union
and Eastern Germany. Most such procedures were performed from the 1970s to the 1990s. Although only a few case reports have been published,
all of which involved complications that appeared several years after the procedure, it appears that, surprisingly, this nonvascularized and incompati-
ble immunologic tissue is relatively well tolerated. We present the case of a 45-year-old Russian woman who underwent breast explantation, due
to breast hardness and pain, 15 years after breast augmentation with cadaveric fat grafting. Through genetic studies, we conﬁrmed that the host
and the graft were HLA incompatible. Moreover, results of analyses excluded the possibility of an acute or chronic immunologic rejection by
the host. We suppose that the early complications that often occur in such cases might result from a nonspeciﬁc, inﬂammatory reaction induced by
acute tissue ischemia and necrosis, and the late local complications that occur years later may relate more to chronic inﬂammation, due to nonvascu-
larized tissue, than to immunologic rejection. Therefore, we propose that different mechanisms may explain how this allogenic fat tissue could have
been tolerated by the patient’s immune system. We particularly underline the immunomodulatory effect of mesenchymal stem cells, which are
abundant in adipose tissues. This characteristic of fat tissue should be investigated further to assess its potential in treating autoimmune diseases or
reducing the likelihood of allograft rejections.
Level of Evidence: 5
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Before the advent of silicone prostheses, numerous materi-
als were utilized for breast augmentation, including ivory,
glass, cellulose, sponges, rubber, plastic, and parafﬁn. From
the 1970s to the 1990s, even cadaveric fat allografts were
used in Eastern European countries, particularly the Soviet
Union.1-8 Our knowledge of this procedure is limited to the
few complications that have been reported; we found no
technical description of the surgery itself in the internation-
al medical literature. However, our research indicates that
in this technique a fat block harvested from the buttocks of
a cadaver is transplanted to the patient’s breast through a
submammary incision, similar to the implantation tech-
nique for silicone prostheses.
Through a case study of breast augmentation with a
homologous cadaveric fat graft, we attempt to understand
how this nonvascularized and immune-incompatible fat
tissue could be tolerated for many years.
CASE PRESENTATION
A healthy 45-year-old Russian woman was referred to our
department by an oncologist in 2005. At presentation, she
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was free of infection and immune disease (eg, human im-
munodeﬁciency virus). According to the patient, she had
undergone bilateral augmentation mammaplasty in 1990 in
the Soviet Union via “a speciﬁc technique without breast
implant.” The immediate postoperative period had been
marked by signs of local inﬂammation of the breasts, accom-
panied by fever and asthenia, which resolved without any
treatment (eg, antibiotics, immunosuppressors) by 3 months
postoperatively. Since 1991, she presented sporadic subcuta-
neous nodules, which disappeared spontaneously, and
progressive breast hardness. While breastfeeding 9 years
after the procedure, the patient had episodes of mastitis that
resolved with antibiotic therapy. Beginning in 2002, her
breasts became painful, and occasional sterile discharge
emerged from subcutaneous nodules. Malignancy was
excluded by biopsy and ultrasonography ﬁndings.
Our ﬁrst visit with the patient occurred 15 years after her
breast augmentation procedure. We noted that the breasts
were hard and deformed, with inframammary scars on
both sides. In the right breast, we detected a subcutaneous
Figure 1. (A, C) Pre-explantation images of the 45-year-old woman, obtained 15 years after breast augmentation with cadaveric
fat grafting. (B, D) Two years after explantation.
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ﬂuctuating nodule, measuring 2× 3 cm, which was
covered by inﬂamed skin (Figure 1A,C).
Magnetic resonance imaging of each breast revealed a sub-
glandular mass with heterogeneous signal on T1/T2, compati-
ble with fat tissue and some vacuoles in the center (Figure 2).
Each mass was surrounded by a thick capsule. On the right
breast a herniation of this tissue to the skin was noted.
Bilateral explantation of these “breast implants” was
performed. A yellowish mass (measuring 7.5× 5×4.5 cm),
compatible with necrotic fat tissue, was excised from each
breast. These masses were surrounded by a hard and
calciﬁed capsule, which was difﬁcult to dissect from the
breast gland (Figure 3). The large subcutaneous nodule in
the right breast, corresponding to herniated necrotic fat,
was excised. Immediate and 1 year post-operatively was
free of any medical event and patient didn't present any
discomfort. The breasts were ptotic and empty in the
upper pole, with a retracted scar in the internal quadrant
on the right breast where the herniated nodule had been
excised (Figure 1B,D).
Macroscopic examination showed a thick, 2 mm, calci-
ﬁed capsule surrounding necrotic adipose tissue. The inter-
nal part included focal areas of calciﬁcation and a central
cystic degeneration that contained oils (Figure 4A).
Microscopic analysis conﬁrmed a calciﬁed capsule rich
in collagen and devoid of inﬂammation. This capsule de-
limited a 6× 5 cm mass of adipose tissue, which was
completely mummiﬁed and necrotic. The mass contained
several cysts and no inﬂammatory cells (Figure 4B). Focally,
on the periphery of the capsule, in the breast parenchyma
that was minimally resected with the mass, synovial meta-
plasia with a xanthogranulomatous inﬂammation was
observed; it was rich in macrophages but poor in lympho-
cytes (Figure 4C). A specimen obtained intraoperatively for
bacterial analysis tested negatively.
All information concerning the donor was unknown
to the patient, and therefore to us. Hence, to conﬁrm the
allogenic origin of the fat graft, genetic studies were
ordered. Results showed that the excised grafted fat was
HLA-incompatible. In the effort to determine a potential
immunologic reaction between the host and the graft,
anti-HLA antibody analysis was conducted by enzyme-
linked immunosorbent assay. In cases of graft-vs-host re-
jection, these antibodies usually are positive.
Interestingly, in our patient, the biopsy specimen and
blood testing were negative for anti-HLA class I and II
antibodies.
Figure 2. Pre-explantation magnetic resonance image
(obtained 15 years after cadaveric fat breast augmentation pro-
cedure) demonstrates bilateral subglandular masses (*), each
measuring 8× 7× 5 cm, compatible with fat tissue signal.
The masses are heterogeneous, including some vacuoles in the
center, and are surrounded by an intact thick capsule (arrow).
On the right breast, note the herniation of this tissue to the
skin (#).
Figure 3. Intraoperative images. (A) Difﬁcult dissection of the right cadaveric fat implant, which was surrounded by a thick
capsule from the mammary tissue. (B) Appearance after bilateral explantation.
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DISCUSSION
In a review of the literature, we found only 6 articles (rep-
resenting 26 cases) on patients who underwent breast
augmentation with allograft fat between 1966 and 1991,
most of which were from the Soviet Union and Eastern
Germany. As in the present case, the fat was not injected
but rather implanted through a 4 to 6 cm submammary
incision. In all 6 reports, complications that required post-
operative management were described.1-8 Interestingly,
the complaints in most of these cases were similar to those
of our patient: moderate local and systemic inﬂammatory
reactions occurred within several months of the surgery,
followed by local pain and hardness many years later, ulti-
mately leading to excision.
To our knowledge, the present case is the ﬁrst in which
genetic studies were performed to conﬁrm HLA incompati-
bility between the host and the graft. Subsequently, to in-
vestigate the presence of an immune response against the
graft, immunologic testing was conducted. However, we
did not detect any antibody against the graft, which ex-
cludes acute or chronic immunologic rejection by the
host. Furthermore, histopathologic analyses demonstrated
only macrophages (a nonspeciﬁc immune reaction) and no
lymphocytic reaction was noted, as is usually present in
host-against-graft rejection. This observation of probable
immunotolerance of an implanted allogenic tissue in the
absence of immunosuppressor therapy is surprising. We
hypothesized different possibilities that might explain this
phenomenon:
Figure 4. Histopathologic images. (A) Macroscopic view of the right (R) and left (L) masses after a difﬁcult cut, due to the hard calciﬁed
capsule. In the center, note the complete necrotic adipose tissuewith focal areas of calciﬁcation and a central cystic degeneration con-
taining oils. An additional piece, corresponding to the herniated mass, was resected from the right breast (*). (B) Microscopic view of
the thick ﬁbrous capsule (*) surrounding the mummiﬁed cadaveric tissue (#) and containing dead adipocytes and calciﬁcation (arrow).
Hematoxylin and eosin stain, original magniﬁcation×20. (C) Breast tissue at the periphery of the graft demonstrates a macrophagic
and giant cell reaction (xanthogranulomatous) poor in lymphocytes. Hematoxylin and eosin stain, original magniﬁcation×400.
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(1) The isolation of grafted tissue from the patient’s
immune system. Because the fat graft was nonvascular-
ized, initially only the surrounding part was exposed to
the patient’s immune cells, which could stimulate an
immunologic reaction. Later, the thick ﬁbrotic capsule
developed around the allogenic tissue, which could
isolate it further from the patient’s immune system.
(2) The low immunogenicity of fat tissue. Because the liter-
ature concerning the speciﬁc immunogenicity of fat
tissue is very limited, further assessments are needed.
(3) The immunomodulatory property of adipose-derived
mesenchymal stem cells (MSCs). This has been demon-
strated recently in the literature and, in our opinion, is
the most interesting explanation.
MSCs are stromal cells known for their limitless capacity
for differentiation into bone, fat, muscular, nervous, or endo-
thelial cells, according to their environment.9 They are
present in most tissues (including bone marrow, adipose
tissue, skin, placenta, and heart) and are key elements of
tissue regeneration. Recently, it has been shown that adipose
tissue contains 1000 times more MSCs than the bone
marrow, which initially was regarded as the best source of
stem cells.10 The immunogenicity of MSCs is low due to their
low expression of the HLA class I cell marker and lack of the
class II marker on their cell surface.11 Moreover, recent
studies have demonstrated the potent capacity of MSCs to
inhibit the activation and proliferation of immune cells in-
volved in both acute and chronic phases of immunologic re-
jection of noncompatible tissue by the host. Lymphocytic
reaction is primordial, with T cells and B cells playing key
roles. In a variety of experimental conditions, MSCs have sup-
pressed this lymphocyte proliferative response to allogenic or
xenogenic antigens through a number of mechanisms.12-16
MSCs modulate the activation, proliferation, and func-
tioning of T cells.17-19 Although MSCs strongly suppress
CD8+ cytotoxic T lymphocytes (CTL), they themselves are
resistant to CTL-mediated lysis.14,20,21 In addition to their
effects on naïve T-cell populations, MSCs inhibit the prolif-
eration of memory T cells.19,20 Some investigators have
found that MSCs effectively inhibit B-cell proliferation, dif-
ferentiation, and antibody production,22 as well as suppress
the production of interferon-gamma and interleukin-2,
which normally stimulate natural killer cells.20,23
Based on these data, it has been proposed that MSCs can
contribute to controlling auto-immune diseases such as
rheumatoid arthritis and multiple sclerosis. Their effective-
ness in humans is under investigation in different clinical
trials. The immunomodulatory properties of MSCs suggest
that they may play a role in bone marrow and solid-organ
transplantation by preventing rejection. This ability has
been demonstrated by MSCs infusions to murine models of
allogenic bone marrow,24 skin,12 and liver25 grafts, where
graft-versus-host disease was prevented.
The application of MSCs to bone marrow transplantation
has also been investigated in human studies: various groups
have shown that administration of MSCs not only increases
bone marrow engraftment after hematopoietic stem cell tran-
splantation, but also reduces conventional therapy-resistant
host-versus-graft disease.26,27 The effectiveness of MSCs
in solid-organ transplantation is a relatively new area of
research.28 Therefore, the immunomodulatory effect of
MSCs that is present abundantly in the fat graft might be re-
sponsible, in part, for the immuotolerance of the allogenic fat
implanted in the breast. Furthermore, it can be supposed that
fat tissue was in some way isolated from the immunologic
reaction: the grafted tissue was not vascularized and, except
for the periphery, was not in contact with the immune sys-
tem. Later, the nonvascularized capsule isolated the grafted
tissue from the immunologic reaction. Some investigators
purport that the grafted tissue had been embedded in a
plastic sac in order to isolate it from the immune system.3
Although breast augmentation by homologous fat tissue
appears to provide seemingly satisfactory immediate results,
complications may arise after several years. Late complica-
tions of this procedure have been attributable more so to fat
necrosis than to immunologic reaction. The physiologic turn-
over of adipocytes is 3 months. As demonstrated by Eto
et al;29 most graft adipocytes that are further than 3 mm
from a vessel begin to die in the ﬁrst 24 hours. Stem cells
better support the ischemia; they survive up to 5-7 mm from
an oxygen source. Thus, when a big piece of fat is trans-
planted as a prosthesis rather than being injected during a
cadaveric breast augmentation procedure, it is not surprising
that most adipocytes will die within 3 days but some stem
cells will survive. Except for cells in the periphery, grafted
tissue is isolated from oxygen and undergoes necrosis during
the ﬁrst postoperative days, especially in the center. This
narcotization provokes oil cysts and a chronic nonlympho-
cytic immune reaction, resulting in multiple granulomas, as
we have demonstrated by histopathologic analysis. We
suppose that the early complications that often occur in such
cases might result from a nonspeciﬁc, inﬂammatory reaction
induced by acute tissue ischemia and necrosis. However, the
late local complications that occur years later as mastitis,
nodules, pain, and breast hardness, without systemic reac-
tion, may relate more to chronic inﬂammation, due to non-
vascularized tissue, than to immunologic rejection.
CONCLUSIONS
Although cadaveric breast augmentation likely has been
abandoned entirely, the existing case reports have raised in-
teresting questions about the potential immunomodulatory
effect of fat tissue. This characteristic of fat tissue should be
investigated for its potential in the treatment of autoim-
mune disease (eg, scleroderma) and in reducing the likeli-
hood of allograft rejection (eg, facial transplantation).
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